Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Publication Type:

Journal Article

Authors:

Jänne, Pasi A; Ou, Sai-Hong I; Kim, Dong-Wan; Oxnard, Geoffrey R; Martins, Renato; Kris, Mark G; Dunphy, Frank; Nishio, Makoto; O'Connell, Joseph; Paweletz, Cloud; Taylor, Ian; Zhang, Hui; Goldberg, Zelanna; Mok, Tony

Source:

The Lancet. Oncology, Volume 15, Issue 13, p.1433-41 (2014)

Keywords:

Adult, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Targeted Therapy, Mutation, Neoplasm Staging, Prognosis, Quinazolinones, Receptor, Epidermal Growth Factor, Survival Rate

Abstract:

Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib. However, resistance inevitably develops, and more effective EGFR inhibitors are needed. Dacomitinib is a covalent pan-HER inhibitor that has shown clinical activity in patients previously treated with gefitinib or erlotinib. We did a trial of dacomitinib as initial systemic therapy in clinically and molecularly selected patients with advanced non-small-cell lung cancer.